Todd A. Davies
Research Subjects
Todd A. Davies has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Karen Bush
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey
9 shared publicationsAlan Evangelista
Ortho-McNeil Inc., Raritan, New Jersey
4 shared publicationsRaul Goldschmidt
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey
4 shared publicationsWenchi Shang
Johnson and Johnson Pharmaceutical Research and Development LLC, Raritan, New Jersey
4 shared publicationsDaniel F. Sahm
2 shared publicationsRobert K. Flamm
Johnson and Johnson Pharmaceutical Research and Development LLC, Raritan, New Jersey
2 shared publications
Latest Publications
- 15 September 2008
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 120 (3 uppl 1) , 39-46
Decline in the Prevalence of Pandemic Clones Spain23F-1 and Spain9V-3 Among US Fluoroquinolone-Resistant
Fluoroquinolone-resistant variants of pandemic clones Spain(23F)-1, Spain(6B)-2, Spain(9V)-3, and Spain(14)-5 have been seen in various regions of the United States and the world, leading to the speculation that fluoroquinolone resistance among US Streptococcus pneumoniae may increase because of clonal spread. Using levofloxacin as a representative of the fluoroquinolone class, all 196 levofloxacin-resistant pneumococci from a total of 22 794 isolates in the Tracking Resistance in the United States Today (TRUST) 5-8 studies (2001-2004) were subjected to pulsed-field gel electrophoresis (PFGE), serotyping, and sequencing of parC/E and gyrA/B quinolone resistance-determining regions (QRDR) to measure the extent of clonality. In addition, susceptibility testing of these isolates to ciprofloxacin, gatifloxacin, levofloxacin, and moxifloxacin was performed. ATCC type strains of Spain(23F)-1, Spain(6B)-2, Spain(9V)-3, and Spain(14)-5 clones were included as comparators. Levofloxacin-resistant isolates with Spain(23F)-1-related PFGE patterns decreased from 28% of the resistant isolates in 2001 to 6% in 2004. These isolates, with serotypes 23F (n = 17), 19F (n = 17), or 19A (n = 1), had 15 different QRDR profiles and were all ciprofloxacin- and gatifloxacin-resistant. Levofloxacin-resistant isolates with Spain(9V)-3-related PFGE patterns decreased from 13% of the resistant isolates in 2001 to 2% in 2004. The Spain(9V)-3-related isolates were serotype 9V (n = 9), 9A (n = 2), and 9N (n = 1) and exhibited 6 different QRDR profiles. All were resistant to all fluoroquinolones tested. None of the levofloxacin-resistant isolates had PFGE patterns related to Spain(6B)-2 or Spain(14)-5. Resistance to respiratory fluoroquinolones among pneumococci has remained constant at about 1% (0.8%-1.1%) since 2001, and there has been a decrease in the prevalence of levofloxacin-resistant isolates similar to Spain(23F)-1 or Spain(9V)-3. Considerable QRDR variability among these strains appears to be the result of sporadic independent mutational events as opposed to clonal expansion.
- 15 September 2008
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 120 (3 uppl 1) , 39-46
Decline in the Prevalence of Pandemic Clones Spain23F-1 and Spain9V-3 Among US Fluoroquinolone-Resistant
Fluoroquinolone-resistant variants of pandemic clones Spain(23F)-1, Spain(6B)-2, Spain(9V)-3, and Spain(14)-5 have been seen in various regions of the United States and the world, leading to the speculation that fluoroquinolone resistance among US Streptococcus pneumoniae may increase because of clonal spread. Using levofloxacin as a representative of the fluoroquinolone class, all 196 levofloxacin-resistant pneumococci from a total of 22 794 isolates in the Tracking Resistance in the United States Today (TRUST) 5-8 studies (2001-2004) were subjected to pulsed-field gel electrophoresis (PFGE), serotyping, and sequencing of parC/E and gyrA/B quinolone resistance-determining regions (QRDR) to measure the extent of clonality. In addition, susceptibility testing of these isolates to ciprofloxacin, gatifloxacin, levofloxacin, and moxifloxacin was performed. ATCC type strains of Spain(23F)-1, Spain(6B)-2, Spain(9V)-3, and Spain(14)-5 clones were included as comparators. Levofloxacin-resistant isolates with Spain(23F)-1-related PFGE patterns decreased from 28% of the resistant isolates in 2001 to 6% in 2004. These isolates, with serotypes 23F (n = 17), 19F (n = 17), or 19A (n = 1), had 15 different QRDR profiles and were all ciprofloxacin- and gatifloxacin-resistant. Levofloxacin-resistant isolates with Spain(9V)-3-related PFGE patterns decreased from 13% of the resistant isolates in 2001 to 2% in 2004. The Spain(9V)-3-related isolates were serotype 9V (n = 9), 9A (n = 2), and 9N (n = 1) and exhibited 6 different QRDR profiles. All were resistant to all fluoroquinolones tested. None of the levofloxacin-resistant isolates had PFGE patterns related to Spain(6B)-2 or Spain(14)-5. Resistance to respiratory fluoroquinolones among pneumococci has remained constant at about 1% (0.8%-1.1%) since 2001, and there has been a decrease in the prevalence of levofloxacin-resistant isolates similar to Spain(23F)-1 or Spain(9V)-3. Considerable QRDR variability among these strains appears to be the result of sporadic independent mutational events as opposed to clonal expansion.
- 15 September 2008
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 120 (3 uppl 1) , 25-32
Sporadic Occurrences of Fluoroquinolone-Resistant Streptococcus pneumoniae in the United States: Longitudinal Analysis of Institutions from the New England and West South Central Regions During the TRUST 4-9 (2000-2005) Surveillance Studies
Twenty-six institutions in New England and 24 institutions in West South Central regions participating in the Tracking Resistance in the United States Today (TRUST) 4-9 surveillance studies (2000-2005) were monitored for levofloxacin-resistant Streptococcus pneumoniae to determine if resistance was sporadic or persistent. Levofloxacin was used as a representative of the respiratory fluoroquinolones. Levofloxacin-resistant isolates were identified in 8 of the 26 New England institutions and in 11 of the 24 West South Central institutions during the surveillance period. Resistant isolates were recovered in consecutive years from 3 institutions: 1 each in Massachusetts, Oklahoma, and Texas. In total, 34 levofloxacin-resistant isolates (14 from New England, 20 from the West South Central region) were identified over the 6-year period. Two of these isolates from an institution in Connecticut and 2 from an institution in Oklahoma had the same serotype, pulsed-field gel electrophoresis pattern, and quinolone resistance-determining region (QRDR) mutations. States with elevated pneumococcal levofloxacin resistance rates, compared with the national average, did not maintain this status in consecutive years. Based on data from the same institutions over 6 years, levofloxacin resistance among US pneumococci has been sporadic, nonclonal, and rare.
- 15 September 2008
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 120 (3 uppl 1) , 25-32
Sporadic Occurrences of Fluoroquinolone-Resistant Streptococcus pneumoniae in the United States: Longitudinal Analysis of Institutions from the New England and West South Central Regions During the TRUST 4-9 (2000-2005) Surveillance Studies
Twenty-six institutions in New England and 24 institutions in West South Central regions participating in the Tracking Resistance in the United States Today (TRUST) 4-9 surveillance studies (2000-2005) were monitored for levofloxacin-resistant Streptococcus pneumoniae to determine if resistance was sporadic or persistent. Levofloxacin was used as a representative of the respiratory fluoroquinolones. Levofloxacin-resistant isolates were identified in 8 of the 26 New England institutions and in 11 of the 24 West South Central institutions during the surveillance period. Resistant isolates were recovered in consecutive years from 3 institutions: 1 each in Massachusetts, Oklahoma, and Texas. In total, 34 levofloxacin-resistant isolates (14 from New England, 20 from the West South Central region) were identified over the 6-year period. Two of these isolates from an institution in Connecticut and 2 from an institution in Oklahoma had the same serotype, pulsed-field gel electrophoresis pattern, and quinolone resistance-determining region (QRDR) mutations. States with elevated pneumococcal levofloxacin resistance rates, compared with the national average, did not maintain this status in consecutive years. Based on data from the same institutions over 6 years, levofloxacin resistance among US pneumococci has been sporadic, nonclonal, and rare.
- 1 September 2008
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 14 (3) , 187-196
Effects of the 7-Valent Pneumococcal Conjugate Vaccine on U.S. Levofloxacin-Resistant Streptococcus pneumoniae
Background: Seven-valent pneumococcal conjugate vaccine (PCV7) provides protection against invasive pneumococcal disease that extends to unvaccinated populations, such as elderly or immunocompromised adults. PCV7 also reduces incidence of pneumococcal penicillin resistance. In this study, the potential impact of PCV7 on pneumococcal fluoroquinolone resistance was examined. Methods: U.S. levofloxacin-resistant isolates (264) from TRUST surveillance studies (1999–2004) were serotyped and quinolone resistance–determining region of parC/E and gyrA/B sequenced. Changes in prevalence of vaccine/nonvaccine serotypes during 2000–2004 and 1999–2004 were analyzed by regression analyses and chi-square trend test. Results: The introduction of PCV7 (2000–2004) did not affect fluoroquinolone resistance prevalence, but mutants with vaccine serotypes declined linearly at −6.6 ± 0.8% per year ( p = 0.003), with concomitant replacement by nonvaccine serotypes; vaccine-related serotypes (6A, 9N, 19A, and 23N) increased ( p = 0.04). Differential selection between vaccine and nonvaccine serotypes occurred for mutants containing amino acid substitutions at either ParC Ser79 ( p = 0.01) or both ParC Ser79 and GyrA Ser81 ( p = 0.04). Among mutants with ParC Ser79 substitutions, vaccine serotypes declined linearly ( p = 0.02), whereas nonvaccine serotypes increased ( p = 0.04). Additionally, a vaccine-independent effect became apparent during 1999–2004, as the incidence of ParC Ser79 and Asp83 mutations declined in fluoroquinolone-resistant strains, suggesting that these substitutions conferred decreased fitness. Conclusions: PCV7 has led to extensive replacement of vaccine serotypes by nonvaccine serotypes among levofloxacin-resistant pneumococci.
- 1 September 2008
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 14 (3) , 187-196
Effects of the 7-Valent Pneumococcal Conjugate Vaccine on U.S. Levofloxacin-Resistant Streptococcus pneumoniae
Background: Seven-valent pneumococcal conjugate vaccine (PCV7) provides protection against invasive pneumococcal disease that extends to unvaccinated populations, such as elderly or immunocompromised adults. PCV7 also reduces incidence of pneumococcal penicillin resistance. In this study, the potential impact of PCV7 on pneumococcal fluoroquinolone resistance was examined. Methods: U.S. levofloxacin-resistant isolates (264) from TRUST surveillance studies (1999–2004) were serotyped and quinolone resistance–determining region of parC/E and gyrA/B sequenced. Changes in prevalence of vaccine/nonvaccine serotypes during 2000–2004 and 1999–2004 were analyzed by regression analyses and chi-square trend test. Results: The introduction of PCV7 (2000–2004) did not affect fluoroquinolone resistance prevalence, but mutants with vaccine serotypes declined linearly at −6.6 ± 0.8% per year ( p = 0.003), with concomitant replacement by nonvaccine serotypes; vaccine-related serotypes (6A, 9N, 19A, and 23N) increased ( p = 0.04). Differential selection between vaccine and nonvaccine serotypes occurred for mutants containing amino acid substitutions at either ParC Ser79 ( p = 0.01) or both ParC Ser79 and GyrA Ser81 ( p = 0.04). Among mutants with ParC Ser79 substitutions, vaccine serotypes declined linearly ( p = 0.02), whereas nonvaccine serotypes increased ( p = 0.04). Additionally, a vaccine-independent effect became apparent during 1999–2004, as the incidence of ParC Ser79 and Asp83 mutations declined in fluoroquinolone-resistant strains, suggesting that these substitutions conferred decreased fitness. Conclusions: PCV7 has led to extensive replacement of vaccine serotypes by nonvaccine serotypes among levofloxacin-resistant pneumococci.
- 1 April 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (4) , 1510-1512
Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa
Doripenem, a parenteral carbapenem, exhibited high affinity for penicillin-binding protein 2 (PBP2) and PBP3 in Pseudomonas aeruginosa and PBP2 in Escherichia coli , the primary PBPs whose inhibition leads to cell death. This PBP affinity profile correlates with the broad-spectrum gram-negative activity observed with doripenem.
- 1 April 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (4) , 1510-1512
Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa
Doripenem, a parenteral carbapenem, exhibited high affinity for penicillin-binding protein 2 (PBP2) and PBP3 in Pseudomonas aeruginosa and PBP2 in Escherichia coli , the primary PBPs whose inhibition leads to cell death. This PBP affinity profile correlates with the broad-spectrum gram-negative activity observed with doripenem.
- Open Access
- 31 January 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 61 (3) , 751-753
Activity of doripenem and comparator -lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x
- 31 January 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 61 (3) , 751-753
Open AccessActivity of doripenem and comparator -lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x
- 1 January 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (1) , 378-381
Characterization and Dynamics of Middle Ear Fluid and Nasopharyngeal Isolates of Streptococcus pneumoniae from 12 Children Treated with Levofloxacin
Children who had acute otitis media and were treated with levofloxacin were assessed for the emergence of fluoroquinolone-resistant Streptococcus pneumoniae . Nasopharynx cultures were obtained from patients at the entry to and during levofloxacin therapy. All nasopharynx isolates ( n = 59) from 12 children were levofloxacin susceptible without parC/E or gyrA/B mutations. Pneumococcal nasopharynx persistence was not associated with levofloxacin resistance.
- 1 January 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (1) , 378-381
Characterization and Dynamics of Middle Ear Fluid and Nasopharyngeal Isolates of Streptococcus pneumoniae from 12 Children Treated with Levofloxacin
Children who had acute otitis media and were treated with levofloxacin were assessed for the emergence of fluoroquinolone-resistant Streptococcus pneumoniae . Nasopharynx cultures were obtained from patients at the entry to and during levofloxacin therapy. All nasopharynx isolates ( n = 59) from 12 children were levofloxacin susceptible without parC/E or gyrA/B mutations. Pneumococcal nasopharynx persistence was not associated with levofloxacin resistance.
- 1 July 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (7) , 2621-2624
Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli , Pseudomonas aeruginosa , Staphylococcus aureus , and Streptococcus pneumoniae
Ceftobiprole exhibited tight binding to PBP2a in methicillin-resistant Staphylococcus aureus , PBP2x in penicillin-resistant Streptococcus pneumoniae , and PBP3 and other essential penicillin-binding proteins in methicillin-susceptible S. aureus , Escherichia coli , and Pseudomonas aeruginosa . Ceftobiprole also bound well to PBP2 in the latter organisms, contributing to the broad-spectrum antibacterial activity against gram-negative and gram-positive bacteria.
- 1 July 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (7) , 2621-2624
Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli , Pseudomonas aeruginosa , Staphylococcus aureus , and Streptococcus pneumoniae
Ceftobiprole exhibited tight binding to PBP2a in methicillin-resistant Staphylococcus aureus , PBP2x in penicillin-resistant Streptococcus pneumoniae , and PBP3 and other essential penicillin-binding proteins in methicillin-susceptible S. aureus , Escherichia coli , and Pseudomonas aeruginosa . Ceftobiprole also bound well to PBP2 in the latter organisms, contributing to the broad-spectrum antibacterial activity against gram-negative and gram-positive bacteria.
- 1 July 2006
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (7) , 2530-2532
Activities of Ceftobiprole and Other β-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x
The activities of ceftobiprole and other β-lactams were examined with 30 Streptococcus pneumoniae isolates containing multiple pbp1a , pbp2b , and pbp2x mutations. The highest ceftobiprole MIC was 1 μg/ml, while the comparator MICs were 16 to 64 μg/ml. Fifty percent inhibitory concentrations for penicillin-binding protein 2x were 0.5 μg/ml (ceftobiprole) and 4 μg/ml (ceftriaxone) in a penicillin- and ceftriaxone-resistant isolate.
- 1 July 2006
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (7) , 2530-2532
Activities of Ceftobiprole and Other β-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x
The activities of ceftobiprole and other β-lactams were examined with 30 Streptococcus pneumoniae isolates containing multiple pbp1a , pbp2b , and pbp2x mutations. The highest ceftobiprole MIC was 1 μg/ml, while the comparator MICs were 16 to 64 μg/ml. Fifty percent inhibitory concentrations for penicillin-binding protein 2x were 0.5 μg/ml (ceftobiprole) and 4 μg/ml (ceftriaxone) in a penicillin- and ceftriaxone-resistant isolate.
- Open Access
- 23 January 2006
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 57 (3) , 437-442
Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999–2003)
Objectives: Prevalence of single quinolone-resistance determining region (QRDR) mutations in Streptococcus pneumoniae was studied from nine institutions over 5 years to track the incidence of single QRDR mutations. Methods: All 1106 levofloxacin-susceptible pneumococci (MICs ≤2.0 mg/L) identified from 1112 total isolates (99.5% susceptibility) in TRUST 3 (1999), TRUST 5 (2001) and TRUST 7 (2003) surveillance studies from the same nine hospitals in nine states were screened for QRDR mutations. Using pyrosequencing, the strains were screened for mutations corresponding to hot spots Asp-78, Ser-79 and Asp-83 in ParC; Asp-80, Ser-81 and Glu-85 in GyrA; Asp-435 in ParE and Asp-435 in GyrB. DNA sequencing of QRDRs was performed to confirm mutations. Results: No QRDR mutations were found in any of the isolates with levofloxacin MICs ≤0.5 mg/L and no gyrA or gyrB QRDR mutations were found in any of the screened isolates (MICs ≤2 mg/L). Four single-step QRDR mutants with the following amino acid substitutions were found: ParE Asp-435 to Asn (isolated in 1999 in Colorado); ParC Asp-83 to Asn (isolated in 2001 in Kentucky); ParC Ser-79 to Phe (isolated in 2003 in Indiana) and ParC Ser-79 to Tyr (isolated in 2003 in California). These non-clonal strains had levofloxacin MICs of 1 mg/L and were non-susceptible to ciprofloxacin (MIC 2–4 mg/L). Conclusions: Overall prevalence of single QRDR mutations in levofloxacin-susceptible S. pneumoniae with MICs of ≤2 mg/L was 0.4% (4/1106) and has remained <1% within nine institutions over 5 years (1999–2003).
- 23 January 2006
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 57 (3) , 437-442
Open AccessInfrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999–2003)
Objectives: Prevalence of single quinolone-resistance determining region (QRDR) mutations in Streptococcus pneumoniae was studied from nine institutions over 5 years to track the incidence of single QRDR mutations. Methods: All 1106 levofloxacin-susceptible pneumococci (MICs ≤2.0 mg/L) identified from 1112 total isolates (99.5% susceptibility) in TRUST 3 (1999), TRUST 5 (2001) and TRUST 7 (2003) surveillance studies from the same nine hospitals in nine states were screened for QRDR mutations. Using pyrosequencing, the strains were screened for mutations corresponding to hot spots Asp-78, Ser-79 and Asp-83 in ParC; Asp-80, Ser-81 and Glu-85 in GyrA; Asp-435 in ParE and Asp-435 in GyrB. DNA sequencing of QRDRs was performed to confirm mutations. Results: No QRDR mutations were found in any of the isolates with levofloxacin MICs ≤0.5 mg/L and no gyrA or gyrB QRDR mutations were found in any of the screened isolates (MICs ≤2 mg/L). Four single-step QRDR mutants with the following amino acid substitutions were found: ParE Asp-435 to Asn (isolated in 1999 in Colorado); ParC Asp-83 to Asn (isolated in 2001 in Kentucky); ParC Ser-79 to Phe (isolated in 2003 in Indiana) and ParC Ser-79 to Tyr (isolated in 2003 in California). These non-clonal strains had levofloxacin MICs of 1 mg/L and were non-susceptible to ciprofloxacin (MIC 2–4 mg/L). Conclusions: Overall prevalence of single QRDR mutations in levofloxacin-susceptible S. pneumoniae with MICs of ≤2 mg/L was 0.4% (4/1106) and has remained <1% within nine institutions over 5 years (1999–2003).
- Open Access
- 1 July 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (7) , 3031-3033
Predominance of 23S rRNA Mutants among Non-Erm, Non-Mef Macrolide-Resistant Clinical Isolates of Streptococcus pneumoniae Collected in the United States in 1999-2000
A total of 322 erythromycin-resistant pneumococci from TRUST 3 and TRUST 4 United States surveillance studies (1999-2000) were screened for 23S rRNA, L4, and L22 gene mutations. Nineteen isolates, two with mefA, had mutations at position 2058 or 2059 in 23S rRNA. Two had a 69GTG71-to-TPS substitution in L4; one of these also contained ermA.
- 1 July 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (7) , 3031-3033
Open AccessPredominance of 23S rRNA Mutants among Non-Erm, Non-Mef Macrolide-Resistant Clinical Isolates of Streptococcus pneumoniae Collected in the United States in 1999-2000
A total of 322 erythromycin-resistant pneumococci from TRUST 3 and TRUST 4 United States surveillance studies (1999-2000) were screened for 23S rRNA, L4, and L22 gene mutations. Nineteen isolates, two with mefA, had mutations at position 2058 or 2059 in 23S rRNA. Two had a 69GTG71-to-TPS substitution in L4; one of these also contained ermA.